Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.

Original publication

DOI

10.1051/parasite/2011183207

Type

Journal article

Journal

Parasite

Publication Date

08/2011

Volume

18

Pages

207 - 214

Keywords

Aminoquinolines, Animals, Antimalarials, Chloroquine, Clinical Trials, Phase II as Topic, Drug Resistance, Ferrous Compounds, Humans, Malaria, Falciparum, Malaria, Vivax, Plasmodium falciparum, Plasmodium vivax